Cargando…
Acceptance and completion of rifapentine-based TB preventive therapy (3HP) among people living with HIV (PLHIV) in Kampala, Uganda—patient and health worker perspectives
BACKGROUND: A 12-dose, once-weekly regimen of isoniazid and rifapentine (3HP) is effective in preventing tuberculosis (TB) among people living with HIV (PLHIV). We sought to identify potential barriers to and facilitators of acceptance and completion of 3HP treatment from the perspective of people l...
Autores principales: | Semitala, Fred C., Musinguzi, Allan, Ssemata, Jackie, Welishe, Fred, Nabunje, Juliet, Kadota, Jillian L., Berger, Christopher A., Katamba, Achilles, Kiwanuka, Noah, Kamya, Moses R., Dowdy, David, Cattamanchi, Adithya, Katahoire, Anne R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8247167/ https://www.ncbi.nlm.nih.gov/pubmed/34193311 http://dx.doi.org/10.1186/s43058-021-00173-2 |
Ejemplares similares
-
Completion of isoniazid–rifapentine (3HP) for tuberculosis prevention among people living with HIV: Interim analysis of a hybrid type 3 effectiveness–implementation randomized trial
por: Semitala, Fred C., et al.
Publicado: (2021) -
Protocol for the 3HP Options Trial: a hybrid type 3 implementation-effectiveness randomized trial of delivery strategies for short-course tuberculosis preventive therapy among people living with HIV in Uganda
por: Kadota, Jillian L., et al.
Publicado: (2020) -
Preferences of people living with HIV for features of tuberculosis preventive treatment regimens – a discrete choice experiment
por: Aschmann, Hélène E., et al.
Publicado: (2023) -
Identifying barriers to and facilitators of tuberculosis contact investigation in Kampala, Uganda: a behavioral approach
por: Ayakaka, Irene, et al.
Publicado: (2017) -
Evaluating the impact of cash transfers on tuberculosis (ExaCT TB): a stepped wedge cluster randomised controlled trial
por: Shete, Priya B., et al.
Publicado: (2023)